Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Pemphigus - Pipeline Review, H2 2014

Published: Dec-2014 | Format: PDF | Global Markets Direct | Number of pages: 69 | Code: MRS - 18563


Global Markets Directs, Pemphigus Pipeline Review, H2 2014, provides an overview of the Pemphiguss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pemphigus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pemphigus and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Pemphigus
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Pemphigus and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Pemphigus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Pemphigus pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Pemphigus
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Pemphigus pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Contents 2
List of Tables 4
List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Pemphigus Overview 7
Therapeutics Development 8
Pipeline Products for Pemphigus - Overview 8
Pipeline Products for Pemphigus - Comparative Analysis 9
Pemphigus - Therapeutics under Development by Companies 10
Pemphigus - Therapeutics under Investigation by Universities/Institutes 11
Pemphigus - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Pemphigus - Products under Development by Companies 16
Pemphigus - Products under Investigation by Universities/Institutes 17
Pemphigus - Companies Involved in Therapeutics Development 18
Clinuvel Pharmaceuticals Limited 18
Genmab A/S 19
HanAll Biopharma Co., Ltd. 20
Immunomedics, Inc. 21
Momenta Pharmaceuticals, Inc. 22
Novartis AG 23
PinCell srl 24
Pemphigus - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
afamelanotide - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Antibody for Autoimmune Disorders and Inflammation - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
DP-C006 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Drugs to Target HSP27 for Autoimmune Disorders - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
HL-161 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ofatumumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PC-111 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
VAY-736 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
veltuzumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Pemphigus - Recent Pipeline Updates 52
Pemphigus - Dormant Projects 61
Pemphigus - Product Development Milestones 62
Featured News & Press Releases 62
Nov 21, 2014: Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Pemphigus 62
Oct 07, 2014: Stiefel, a GSK company, announces start of phase III study of subcutaneous ofatumumab for pemphigus vulgaris 62
May 22, 2014: Scenesse receives US orphan-drug designation in Hailey-Hailey Disease 63
May 19, 2014: Afamelanotide 16mg recognised for potential to treat rare Hailey-Hailey Disease 64
Feb 10, 2014: Phase II study of SCENESSE in rare skin disorder Hailey-Hailey Disease commences 64
Oct 28, 2013: Positive pilot data published on SCENESSE in rare skin disorder 65
Jul 04, 2013: Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder 66

Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

List of Tables
 

Number of Products under Development for Pemphigus, H2 2014 8
Number of Products under Development for Pemphigus - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Comparative Analysis by Unknown Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Pemphigus - Pipeline by Clinuvel Pharmaceuticals Limited, H2 2014 18
Pemphigus - Pipeline by Genmab A/S, H2 2014 19
Pemphigus - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 20
Pemphigus - Pipeline by Immunomedics, Inc., H2 2014 21
Pemphigus - Pipeline by Momenta Pharmaceuticals, Inc., H2 2014 22
Pemphigus - Pipeline by Novartis AG, H2 2014 23
Pemphigus - Pipeline by PinCell srl, H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Pemphigus Therapeutics - Recent Pipeline Updates, H2 2014 52
Pemphigus - Dormant Projects, H2 2014 61

List of Figures

Number of Products under Development for Pemphigus, H2 2014 8
Number of Products under Development for Pemphigus - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Early Stage Products, H2 2014 14
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Top 10 Targets, H2 2014 26
Number of Products by Stage and Top 10 Targets, H2 2014 26
Number of Products by Top 10 Mechanism of Actions, H2 2014 28
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 28
Number of Products by Top 10 Routes of Administration, H2 2014 30
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 30
Number of Products by Top 10 Molecule Types, H2 2014 32
Number of Products by Stage and Top 10 Molecule Types, H2 2014 32

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing